Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations

Abstract

Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

http://ift.tt/2rTY1Dv